











.jpg)
.avif)
Four broad categories: valuations for regulatory compliance, valuations for financial reporting, transaction valuations, and intangible asset valuations. Each is delivered with a documented methodology aligned to the applicable regulatory standard.
Common triggers include issuance of shares or securities at a premium, transfer of shares whether domestic or cross-border, foreign direct investment into India, overseas investment by Indian entities and individuals, and ESOP issuance. Requirements arise under the Income Tax Act, FEMA, and the Companies Act, and often under more than one simultaneously.
Purchase price allocation following an acquisition, impairment testing for goodwill and intangible assets, evaluation of complex financial instruments, ESOP accounting, and valuation of domestic and overseas investments to facilitate impairment testing.
Yes. We value brands, customer relationships, patented and unpatented technology, non-compete agreements, goodwill, and intellectual property rights, typically in the context of acquisitions, restructuring, or financial reporting.
Our valuation work spans automotive, energy and utilities, pharma and healthcare, financial services, information technology, retail and consumer, industrial products, and media and entertainment, for clients ranging from large listed groups to growth-stage companies.
Reports are prepared to withstand review by auditors, regulators, and transaction counterparties, and the team has represented valuation matters before capital market regulators. Impartiality and a defensible methodology are the basis of every opinion we issue.
Yes. Transaction valuations for M&A, share swaps, fundraising, and corporate restructuring are routinely delivered in coordination with deal timelines, alongside our M&A Tax & Regulatory and Investment Banking teams where the mandate requires it.